Researchers from Georgia State University and biotech startup Da Zen Theranostics have marked a significant advancement in cancer therapy, with their treatment, DZ-002, entering Phase 2 clinical trials.
This innovative therapy harnesses targeted radiation to precisely destroy tumors, potentially transforming cancer treatment and improving the lives of patients who seek better options.
Professor Maged Henary, a chemist and associate chair of the Department of Chemistry at Georgia State, expressed his enthusiasm for this progression.
“It’s deeply rewarding to see DZ-002 advance into Phase 2 trials, marking a promising step forward in cancer treatment and offering hope for improved patient outcomes,
image source from：saportareport
